November 15th 2023
Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
August 11th 2023
Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.
November 30th 2022
Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.
November 17th 2022
Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.
September 7th 2022
Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.